Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Eribulin + Ivonescimab as First-Line Therapy for Advanced Triple-Negative Breast Cancer
ChiCTR2600117652Phase 2Not yet recruiting
- Sponsor
- Sir Run-Run Shaw Hospital
- Start
- Jan 2026
- Modality
- Small Molecules, Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of eribulin and ivonescimab in breast cancer, sponsored by Sir Run-Run Shaw Hospital. Primary endpoint: Objective response rate. Planned start Jan 2026; status: not yet recruiting.
02
Drugs
eribulinivonescimab
03
Conditions
breast cancer
Beyond the preview
Go deeper on ChiCTR2600117652.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2600117652.